Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08YJP
|
|||
| Former ID |
DNC011901
|
|||
| Drug Name |
1-(2-Fluoro-phenyl)-piperazine
|
|||
| Synonyms |
1-(2-Fluorophenyl)piperazine; 1011-15-0; Piperazine, 1-(2-fluorophenyl)-; 1-(2-Fluorophenyl)-piperazine; 1-(2-Fluoro-phenyl)-piperazine; CHEMBL9429; IVTZRJKKXSKXKO-UHFFFAOYSA-N; 1-(2-Fluorophenyl)piperazine, 97%; MFCD00040726; (2-fluorophenyl)piperazine; EINECS 213-780-4; oFPP; PubChem8573; 1-(2-fluorophenyl)piperazinehydrochloride; 2-fluorophenylpiperazine; 2-Fluorophenyl piperazine; ACMC-1BX8H; ortho-fluorophenylpiperazine; 4-(fluorophenyl)piperazine; AC1Q4O5O; AC1Q4L3C; AC1L2EA5; 1-(2-flurophenyl)piperazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H13FN2
|
|||
| Canonical SMILES |
C1CN(CCN1)C2=CC=CC=C2F
|
|||
| InChI |
1S/C10H13FN2/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13/h1-4,12H,5-8H2
|
|||
| InChIKey |
IVTZRJKKXSKXKO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1011-15-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Inhibitor | [1] |
| 5-HT 1D receptor (HTR1D) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.